Compare Crispr Therapeutics AG (CRSP) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Global X Uranium ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Crispr Therapeutics AG and Global X Uranium ETF are close in size by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Global X Uranium ETF for 62 Days on average.
| CRSP | URA | |
|---|---|---|
Market Cap | $4.88B | $5.48B |
Volume | 2,861,747 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $74.92 | $61.81 |
52-Week Low | $44.34 | $37.52 |
Typical Hold Time | 77 Days | 62 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
URA, the Global X Uranium ETF, trades at $38.56, down 3.43% in the last session amid a bearish technical signal. Key support lies at $37, with resistance at $39. The fund provides exposure to uranium miners and nuclear energy companies, benefiting from structural supply deficits and rising demand for reliable power, particularly from AI data centers. Recent index additions like Terra Innovatum and Eagle Nuclear Energy reflect ongoing sector expansion.
The outlook for URA is mixed; long-term demand drivers from nuclear energy adoption and AI power needs are strong, but near-term price volatility and concentrated holdings pose risks. Investors should weigh the sector's growth potential against ETF-specific fluctuations and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
